Recruiting

NAMDCMitochondrial Disease Patient Registry and Biorepository

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
DNA Samples
Who is being recruted

Congenital Abnormalities+78

+ Abnormalities, Multiple

+ Epileptic Syndromes

+6 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: January 2011
See protocol details

Summary

Principal SponsorColumbia University
Study ContactMichio Hirano, MDMore contacts
Last updated: February 4, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 31, 2011

Actual date on which the first participant was enrolled.

Mitochondrial diseases comprise a group of relatively rare (~1 in 5000 adults) but very serious genetic disorders. Mitochondria are often called the "powerhouses of the cell" because they provide the energy our cells need to live. Mitochondria have their own DNA (mtDNA), but they also rely on DNA from the nucleus (nDNA). Mitochondrial diseases are caused by mutations in either mitochondrial or nuclear DNA that result in poorly functioning mitochondria. This can cause a variety of symptoms including muscle weakness, seizures, mental retardation, dementia, hearing loss, blindness, strokes, diabetes, and premature death. Most mitochondrial diseases are progressive, and we are unable to cure most of these diseases with currently available treatments. Research into mitochondrial diseases has been hampered by the low frequency of these disorders and by under-diagnosis by clinicians. This has hindered patient recruitment for research studies and clinical trials. The North American Mitochondrial Disease Consortium (NAMDC) was established to help surmount these issues. Led jointly by Drs. Michio Hirano and Salvatore DiMauro, NAMDC is a consortium of several clinicians and researchers with an interest in mitochondrial disease research in the United States and Canada. By creating a mechanism for the sharing of patient samples with researchers, data and patient contact information, NAMDC will make it easier to conduct clinical and basic laboratory research. Patient information will be shared through the use of the "Patient Data Registry," a specially-designed database, and patient tissue samples will be shared through the use of the "Patient Sample Biorepository", a storage facility in which patient-derived biological samples will be maintained. The Registry and the Biorepository will hopefully accelerate progress in the understanding and treatment of mitochondrial disease. Patients can enroll at any of the NAMDC member sites. A web-based remote enrollment is also available at www.namdc.org for eligible patients who reside far from any of the NAMDC participating sites.

NCT01694940
Principal SponsorColumbia University
Study ContactMichio Hirano, MDMore contacts
Last updated: February 4, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

1000 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Congenital AbnormalitiesAbnormalities, MultipleEpileptic SyndromesAcid-Base ImbalanceAcidosisBrain Diseases, MetabolicCarbohydrate Metabolism, Inborn ErrorsCardiovascular DiseasesCentral Nervous System DiseasesCerebrovascular DisordersChronic DiseaseCranial Nerve DiseasesDiseaseEar DiseasesEndocrine System DiseasesEpilepsyEpilepsy, GeneralizedEpilepsies, MyoclonicEye DiseasesHearing DisordersHeart Defects, CongenitalHeart DiseasesLipid Metabolism, Inborn ErrorsMetabolic DiseasesMetabolism, Inborn ErrorsMuscular DiseasesMusculoskeletal DiseasesCardiomyopathiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNervous System DiseasesNeurologic ManifestationsNeuromuscular DiseasesNutritional and Metabolic DiseasesOphthalmoplegiaOptic AtrophyOptic Nerve DiseasesOtorhinolaryngologic DiseasesParalysisPathologic ProcessesRetinal DegenerationRetinal DiseasesRetinitis PigmentosaSensation DisordersSigns and SymptomsPathological Conditions, Signs and SymptomsVascular DiseasesPyruvate Metabolism, Inborn ErrorsOptic Atrophies, HereditaryEye Diseases, HereditaryOcular Motility DisordersMitochondrial EncephalomyopathiesCardiovascular AbnormalitiesNeurodegenerative DiseasesMyoclonic Epilepsies, ProgressiveHeredodegenerative Disorders, Nervous SystemBrain Diseases, Metabolic, InbornDisease AttributesGenetic Diseases, InbornHearing LossGenetic Diseases, X-LinkedGlucose Metabolism DisordersLipid Metabolism DisordersRetinal DystrophiesCerebral Small Vessel DiseasesAcidosis, LacticBrain DiseasesDeafnessDiabetes MellitusKearns-Sayre SyndromeLeigh DiseaseSyndromeMitochondrial MyopathiesMELAS SyndromeMERRF SyndromeOphthalmoplegia, Chronic Progressive ExternalStrokeMitochondrial DiseasesOptic Atrophy, Hereditary, LeberCytochrome-c Oxidase DeficiencyLeukoencephalopathiesBarth Syndrome

Criteria

4 inclusion criteria required to participate
Adult carriers of known mitochondrial DNA mutations

Medical information and tissue samples are also accepted from deceased individuals who fulfill the above criteria

Patients diagnosed with or suspected to have a mitochondrial disorder

Patients with laboratory analysis indicative of a mitochondrial disorder

2 exclusion criteria prevent from participating
Patients not suspected of carrying a mitochondrial DNA or nuclear DNA mutation that affects mitochondrial function

Patients not suspected of having a mitochondrial disorder

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 17 locations

Recruiting

University of California San Diego

San Diego, United StatesOpen University of California San Diego in Google Maps
Recruiting

Lucile Packard Children's Hospital

Stanford, United States
Recruiting

Children's Hospital of Colorado

Aurora, United States
Recruiting

Children's National Medical Center

Washington D.C., United States
Recruiting
17 Study Centers